Tumor protein‐53 (TP53) germline pathogenic variants are associated with a variety of primary cancers, including soft tissue and bone sarcomas, breast cancer, brain tumors, adrenocortical carcinoma, and leukemia; therefore, patients with TP53 germline pathogenic variants should undergo annual whole‐body medical check‐ups for the secondary prevention of MPCs.46 This evidence concerns the gene TP53 and brain neoplasm.